120 related articles for article (PubMed ID: 3126272)
1. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
Ujike H; Yamamoto M
J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272
[TBL] [Abstract][Full Text] [Related]
2. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
Ogawa N; Yamamoto M; Takayama H
J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
[TBL] [Abstract][Full Text] [Related]
3. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Yamamoto M; Ogawa N; Ujike H
J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
[TBL] [Abstract][Full Text] [Related]
4. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Birkmayer W; Birkmayer G; Lechner H; Riederer P
J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
[TBL] [Abstract][Full Text] [Related]
5. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
[TBL] [Abstract][Full Text] [Related]
6. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
[TBL] [Abstract][Full Text] [Related]
7. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
Kondo T
Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
[No Abstract] [Full Text] [Related]
8. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
Yamamoto M; Ujike H; Ogawa N
Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
[TBL] [Abstract][Full Text] [Related]
9. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
Yoshida M; Noguchi S; Kuramoto S
Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378
[TBL] [Abstract][Full Text] [Related]
10. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
[TBL] [Abstract][Full Text] [Related]
11. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS), an immediate precursor of norepinephrine, on the cerebral blood flow in rats.
Sato E; Irie T; Katsube J
Jpn J Pharmacol; 1987 Jan; 43(1):91-3. PubMed ID: 3106684
[TBL] [Abstract][Full Text] [Related]
12. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
Fukada K; Endo T; Yokoe M; Hamasaki T; Hazama T; Sakoda S
Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
Suzuki T; Sakoda S; Ueji M; Kishimoto S
Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
[TBL] [Abstract][Full Text] [Related]
14. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Tohgi H; Abe T; Takahashi S; Takahashi J; Ueno M; Nozaki Y
Neurosci Lett; 1990 Aug; 116(1-2):194-7. PubMed ID: 2259448
[TBL] [Abstract][Full Text] [Related]
15. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Maruyama W; Naoi M; Narabayashi H
J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
[TBL] [Abstract][Full Text] [Related]
16. Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.
Morimoto S; Matsumura Y; Ohyama T; Shinyama H; Ichihara T; Takahashi Y; Hisaki K
Jpn J Pharmacol; 1990 Mar; 52(3):431-9. PubMed ID: 2110272
[TBL] [Abstract][Full Text] [Related]
17. Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow.
Matsubara S; Sawa Y; Yokoji H; Takamori M
J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):994-7. PubMed ID: 2283531
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease].
Narabayashi H; Yokochi F; Ogawa T; Igakura T
No To Shinkei; 1991 Mar; 43(3):263-8. PubMed ID: 1907469
[TBL] [Abstract][Full Text] [Related]
19. Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy.
Azuma T; Suzuki T; Mizuno R; Tsujino S; Kishimoto S; Mizuta E; Ichikawa K
Acta Neurol Scand; 1988 May; 77(5):409-13. PubMed ID: 3137768
[TBL] [Abstract][Full Text] [Related]
20. The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson's disease.
Nakajima Y; Kagamihara Y; Nagaoka M; Tanaka R
Neurosci Res; 1987 Oct; 5(1):16-27. PubMed ID: 2829065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
